Positive nuclear expression of PHD2 and PHD3 in cancer cells was detected in 98.8% and 75.1% of patients in the Helsinki training cohort and in 72.2% and 44.3% of patients in the Turku validation cohort, respectively. Here, EGLN3 is linked to cancer.